VECTIBIX (panitumumab)
VECTIBIX is indicated for the treatment of Metastatic Colorectal Cancer.
How VECTIBIX Works
Panitumumab binds specifically to the epidermal growth factor receptor (EGFR), a protein overexpressed in colorectal cancers that regulates cellular growth and survival. By competitively inhibiting the binding of natural ligands, the drug prevents receptor activation and the signaling of intracellular proteins involved in tumor proliferation. In the context of KRAS G12C-mutated cancer, EGFR activation serves as a resistance mechanism, and panitumumab works with sotorasib to increase antitumor activity. This process leads to inhibited cell growth, induction of apoptosis, and decreased production of vascular growth factors.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2006-09-27
- Revenue
- $319M (Q4-2025)
- Routes
- IV (INFUSION)
- Dosage Forms
- INJECTABLE
VECTIBIX Approval History
What VECTIBIX Treats
1 indicationsVECTIBIX is approved for 1 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
VECTIBIX Boxed Warning
DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DERMATOLOGIC TOXICITY See full prescribing information for complete boxed warning . Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy...
WARNING: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DERMATOLOGIC TOXICITY See full prescribing information for complete boxed warning . Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy. ( 2.3 , 5.1 , 6.1 )
VECTIBIX Target & Pathway
ProTarget
A receptor tyrosine kinase that promotes cell growth and division. Approximately 20% of breast cancers overexpress HER2, leading to aggressive tumor growth. Targeting HER2 blocks these growth signals and can trigger immune-mediated destruction of cancer cells.
Pathway Context
HER2 forms dimers with other HER family members to activate growth signaling
A receptor that triggers cell growth, proliferation, and survival when activated. Mutations or overexpression of EGFR drive many cancers, particularly lung cancer. Blocking EGFR stops the growth signals that fuel tumor progression.
VECTIBIX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in VECTIBIX's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications VECTIBIX treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to VECTIBIX
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
122 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05638295 | NCI-2022-09876 NCI-2022-09876, EAY191-E5 | Ph 2 | active not recruiting | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) |
| NCT05564377 | NCI-2022-06842 NCI-2022-06842, EAY191 | Ph 2 | recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
| NCT05694936 | VADER | Ph 2 | active not recruiting | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer |
| NCT05747625 | VICCHN2279 NCI-2023-01365 | Ph 1 | recruiting | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma |
| NCT05863195 | EA2222 NCI-2023-02357, EA2222 | Ph 3 | recruiting | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial |
| NCT05198934 CodeBreak300 | 20190172 2024-511187-81-00 | Ph 3 | completed | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation |
| NCT06252649 CodeBreaK 301 | 20210081 | Ph 3 | recruiting | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation |
| NCT05786924 | BDTX-4933-101 2025-523474-16-00 | Ph 1, Ph 2 | recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies |
| NCT02876107 | 2016-0177 NCI-2017-00619, 2016-0177 | Ph 2 | active not recruiting | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer |
| NCT07094204 | 5834-CL-1001 2025-522082-29-00 | Ph 1 | recruiting | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors |
| NCT06820463 AndroMETa-CRC | M24-533 EU CT, 2024-512981-33-00 | Ph 2 | recruiting | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer |
| NCT07172919 | 20250089 2025-522355-26, U1111-1322-4422 | Ph 2 | recruiting | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation |
| NCT06998940 | S2433 NCI-2025-03014, S2433 | Ph 3 | recruiting | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations |
| NCT03384238 | IRB-42237 NCI-2017-01943, PANC0028 | Ph 1, Ph 2 | recruiting | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery |
| NCT05845450 | UNICORN | Ph 2 | recruiting | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) |
| NCT05901545 | VICC-EDHAN23201P NCI-2023-03821 | Ph 1 | recruiting | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer |
| NCT07094113 | 20240031 | Ph 1 | recruiting | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors |
| NCT03510208 | IRB-43179 NCI-2018-00536, BRNCNS0009 | Ph 1, Ph 2 | recruiting | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery |
| NCT04587128 | 2020-0714 2020-0714, NCI-2020-06543 | Ph 2 | active not recruiting | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC |
| NCT06268015 BBOpCo | Pro00115311 | Ph 2 | active not recruiting | Botensilimab and Balstilimab Optimization in Colorectal Cancer |
| NCT04787341 PARERE | EUDRACT 2019-002834-35 | Ph 2 | active not recruiting | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence |
| NCT04163952 results posted | Pro2018002628 NCI-2019-06083, Pro2018002628 | Ph 1 | terminated | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin |
| NCT03087071 | 2016-0338 NCI-2017-00868, 2016-0338 | Ph 2 | active not recruiting | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer |
| NCT03366155 | 180024 18-C-0024 | Ph 2 | completed | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver |
| NCT06332079 HAITI | HAITI 2023-505356-22-00 | Ph 2 | terminated | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients |
| NCT03983993 NIPAVect results posted | IRB00107377 NCI-2018-02757, Winship4517-18 | Ph 2 | active not recruiting | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer |
| NCT06714357 VICTORIA | VICTORIA 2024-514420-16-00 | Ph 2 | recruiting | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer |
| NCT06245356 TRIFLUOX-DP | PRODIGE 91 - UCGI 46 | Ph 2 | recruiting | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
| NCT02593175 results posted | 2015-0294 NCI-2015-02183, 2015-0294 | Ph 2 | completed | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC |
| NCT04185883 | 20190135 2023-506794-35 | Ph 1 | active not recruiting | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) |
| NCT01312857 results posted | 10-137 | Ph 2 | completed | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer |
| NCT06490536 | IFOM-CPT009/2022/PO008 2023-509851-15-00 | Ph 3 | recruiting | The Sagittarius Trial |
| NCT05423197 | IRB-63234 ENT0095 | Ph 2 | not yet recruiting | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC |
| NCT02885753 OSCAR | PRODIGE 49 | Ph 3 | recruiting | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
| NCT03442569 results posted | LCCC1632 | Ph 2 | completed | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC |
| NCT03186326 SAMCO | PRODIGE 54 - FFCD 1603 | Ph 2 | completed | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer |
| NCT06194877 | BGB-3245-EGFR-001 | Ph 1 | terminated | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers |
| NCT01814501 results posted | OSU-11131 NCI-2013-00432 | Ph 2 | completed | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab |
| NCT05121038 CENDIFOX | IIT-2021-CENDIFOX | Ph 1, Ph 2 | active not recruiting | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab |
| NCT05177796 | 2020-0715 NCI-2021-13704, 2020-0715 | Ph 2 | withdrawn | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer |
| NCT03635021 CR-SEQUENCE | TTD-18-01 | Ph 3 | active not recruiting | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer |
| NCT04117945 results posted | ACCRU-GI-1809 NCI-2019-06518, ACCRU-GI-1809 | Ph 2 | active not recruiting | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer |
| NCT03263429 results posted | VICC GI 1703 NCI-2017-01461 | Ph 1, Ph 2 | completed | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer |
| NCT05084859 | SM08502-ONC-03 | Ph 1 | terminated | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors |
| NCT00788957 results posted | 20060447 | Ph 1, Ph 2 | completed | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) |
| NCT06509126 IMPROVE-2 | IMPROVE-2 | Ph 3 | recruiting | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer |
| NCT00891930 results posted | 20070820 2008-004752-77 | Ph 2 | completed | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab |
| NCT01581840 results posted | FFCD 0904 | Ph 1, Ph 2 | completed | Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus |
| NCT02925234 DRUP | M15DRU | Ph 2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT01776307 results posted | BBI608-224 | Ph 2 | completed | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer |
Showing 50 of 122 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VECTIBIX FDA Label Details
Indications & Usage
FDA Label (PDF)VECTIBIX is indicated for the treatment of Metastatic Colorectal Cancer.
WARNING: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]...
Pro Intelligence Preview
Deep insights for VECTIBIX
Revenue Insights
- • Q4-2025: $319M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • 125 total trials
- • Stage: Stable
Competitive Landscape
- • 10 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment